General Atlantic L.P. purchased 4,897,159 shares of Nurix Therapeutics, Inc. The investment is valued at approximately $92.9 million. This acquisition gives General Atlantic a 4.76% ownership stake. The position now ranks as the firm's ninth-largest holding.
Morgan Stanley and Vanguard also recently increased their positions in the company. These moves signal rising institutional confidence in the biotechnology firm.
Nurix recently reported a quarterly loss of $0.79 per share. Quarterly revenue reached $6.25 million. Analysts maintain a consensus Moderate Buy rating despite the wider-than-expected loss. The current consensus price target for the stock is $32.14.